首页 / 院系成果 / 成果详情页

IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models  期刊论文  

  • 编号:
    2c3f07b6-87d7-44ac-afb1-0cba66a37d08
  • 作者:
    Shen, Zhongliang#[1]Liu, Jing(刘晶)#*[2,3]Wu, Jingwen#[1]Zhu, Yuanfei[3];Li, Gaiyun[3];Wang, Jun[1];Luo, Mengjun[3];Deng, Qiang(邓强)[3]Zhang, Jiming(张继明)*[1,3]Xie, Youhua*[3,4]
  • 语种:
    英文
  • 期刊:
    THERANOSTICS ISSN:1838-7640 2019 年 9 卷 13 期 (3798 - 3811)
  • 收录:
  • 关键词:
  • 摘要:

    Chronic hepatitis B virus (HBV) infection causes hepatitis, liver cirrhosis and hepatocellular carcinoma. Covalently closed circular DNA (cccDNA) is the sole viral transcription template and not affected by current treatment options, constituting a key determinant of HBV persistence. Novel therapeutics with demonstrable effectiveness against cccDNA are required.
    Methods: Previously, we established an HBV persistence mouse model using replicon plasmid derived from a clinical isolate (termed BPS) and identified IL-21 as a potent clearance-inducer. We also described another persistence mouse model based on cccDNA mimics produced in vivo termed recombinant cccDNA (rcccDNA). In this work, effectiveness of IL-21-based gene and cellular therapies was tested using these models.
    Results: In both models of HBV persistence, single injections with adeno-associated virus (AAV) expressing murine IL-21 highly efficiently induced clearance of both HBV markers from serum, and more importantly, BPS DNA and rcccDNA from mouse liver. Mechanistically, IL-21-induced clearance was associated with activation and liver infiltration of CD8(+) T cells, and CD8 antibody injections negatively affected AAV-IL-21 effectiveness. More notably, adoptive transfer of CD8 (+) T cells from AAV-IL-21-cured mice engendered clearance in acceptor HBV persistence mice. Furthermore, cured mice were protected against re-challenge with long-lived memory. Most significantly, infusion of splenocytes from treatment-naive mice stimulated ex vivo with IL-21 protein and HBV antigen could also induce clearance in treatment-naive mice.
    Conclusion: These data demonstrate IL-21-based gene and cellular therapies as valid candidates for treating chronic HBV infections, with potential in removing cccDNA-harboring hepatocytes via activated CD8(+) T cells accompanied by long-term protective memory.

  • 推荐引用方式
    GB/T 7714:
    Shen Zhongliang,Liu Jing,Wu Jingwen, et al. IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models [J].THERANOSTICS,2019,9(13):3798-3811.
  • APA:
    Shen Zhongliang,Liu Jing,Wu Jingwen,Zhu Yuanfei,&Xie Youhua.(2019).IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models .THERANOSTICS,9(13):3798-3811.
  • MLA:
    Shen Zhongliang, et al. "IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models" .THERANOSTICS 9,13(2019):3798-3811.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:7 下载次数:0
浏览次数:7
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部